Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Lacosamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 1.00 |
| ▸ | CA3 | P07451 | 1/20 | 1.00 |
| ▸ | CA4 | P22748 | 1/20 | 1.00 |
| ▸ | CA6 | P23280 | 1/20 | 1.00 |
| ▸ | CA5A | P35218 | 1/20 | 1.00 |
| ▸ | CA7 | P43166 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | CA9 | Q16790 | 1/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lacosamide SCHEMBL225889 | 1.00 | CA12 (1.00) | CA12CA1CA2CA3CA4 | |
| Lacosamide SCHEMBL35330 | 1.00 | CA12 (1.00) | CA12CA1CA2CA3CA4 | |
| Lacosamide SCHEMBL28184085 | 0.99 | CA12 (0.97) | CA12CA1CA2CA3CA4 | |
| SCHEMBL8601669 | 0.97 | CA12 (0.94) | CA12CA1CA2CA3CA4 | |
| SCHEMBL12188319 | 0.93 | CA12 (0.87) | CA12CA1CA2CA3CA4 | |
| SCHEMBL24081395 | 0.90 | CA1 (0.82) | CA12CA1CA2CA3CA4 | |
| Lacosamide SCHEMBL12210097 | 0.90 | CA12 (0.82) | CA12CA1CA2CA3CA4 | |
| SCHEMBL527808 | 0.90 | CA12 (0.81) | CA12CA1CA2CA3CA4 | |
| SCHEMBL14931211 | 0.90 | CA12 (0.81) | CA12CA1CA2CA3CA4 | |
| SCHEMBL12168548 | 0.90 | CA12 (0.81) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 604 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3554490-B1 | PHARMACEUTICAL COMBINATION COMPRISING A T-TYPE CALCIUM CHANNEL BLOCKER | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-02-16 | — | — | EP | claimed |
| EP-3519382-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LACOSAMIDE | UNICHEM LAB LTD (IN) | 2021-10-27 | — | — | EP | claimed |
| CN-113061100-A | Novel preparation method of lacosamide | 北京万全德众医药生物技术有限公司 | 2021-07-02 | — | — | CN | claimed |
| EP-2444390-B1 | Process for producing Lacosamide | EUTICALS GMBH (DE) | 2017-02-01 | — | — | EP | claimed |
| EP-2035029-B1 | PEPTIDE COMPOUNDS FOR TREATING REFRACTORY STATUS EPILEPTICUS | UCB PHARMA GMBH (DE) | 2016-11-30 | — | — | EP | claimed |
| CN-103911404-B | A kind of scheme for lacosamide chemical-enzymatic preparation method | NANJING UNIVERSITY (CN) | 2016-01-20 | — | — | CN | claimed |
| CN-104761465-A | Preparation method of lacosamide | SICHUAN TONGSHENG BIOTECHNOLOGY CO LTD | 2015-07-08 | — | — | CN | claimed |
| US-8809585-B2 | Synthesis scheme for lacosamide | UCB PHARMA GMBH (DE) | 2014-08-19 | — | — | US | claimed |
| EP-2046386-B1 | PEPTIDE COMPOUNDS FOR THE TREATMENT OF SKELETAL MUSCLE DISORDERS ASSOCIATED WITH ION CHANNEL DYSFUNCTION | UCB PHARMA GMBH (DE) | 2014-07-23 | — | — | EP | claimed |
| US-20140128377-A1 | METHODS OF TREATING REFRACTORY REPETITIVE SEIZURES | UCB PHARMA GMBH (DE) | 2014-05-08 | — | — | US | claimed |
| EP-1383487-A1 | NOVEL USE OF A PEPTIDE CLASS OF COMPOUND FOR TREATING ALLODYNIA OR OTHER DIFFERENT TYPES OF CHRONIC OR PHANTOM PAIN | SCHWARZ PHARMA AG (DE) | 2004-01-28 | — | — | EP | claimed |
| EP-1373300-A2 | NOVEL USE OF A PEPTIDE CLASS OF COMPOUND FOR TREATING NON NEUROPATHIC INFLAMMATORY PAIN | SCHWARZ PHARMA AG (DE) | 2004-01-02 | — | — | EP | claimed |
| US-20030171300-A1 | Treating different types and symptoms of acute and chronic pain, especially non neuropathic inflammatory pain in mammals. The pain to be treated may be e.g. chronic inflammatory pain, rheumatoid arthritis pain and/or secondary | UCB PHARMA GMBH (DE) | 2003-09-11 | — | — | US | claimed |
| EP-1243263-B1 | Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain | SANOL ARZNEI SCHWARZ GMBH (DE) | 2002-11-27 | — | — | EP | claimed |
| EP-0996435-B1 | AMINO ACID DERIVATIVES USEFUL TO TREAT STROKE | RES CORP TECHNOLOGIES INC (US) | 2002-10-02 | — | — | EP | claimed |
| WO-2002074297-A1 | NOVEL USE OF A PEPTIDE CLASS OF COMPOUND FOR TREATING ALLODYNIA OR OTHER DIFFERENT TYPES OF CHRONIC OR PHANTOM PAIN | SCHWARZ PHARMA AG (DE) | 2002-09-26 | — | — | WO | claimed |
| WO-2002074784-A2 | NOVEL USE OF A PEPTIDE CLASS OF COMPOUND FOR TREATING NON NEUROPATHIC INFLAMMATORY PAIN | SCHWARZ PHARMA AG (DE) | 2002-09-26 | — | — | WO | claimed |
| EP-1243262-A1 | Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain | SCHWARZ PHARMA AG (DE) | 2002-09-25 | — | — | EP | claimed |
| EP-1243263-A1 | Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain | SCHWARZ PHARMA AG (DE) | 2002-09-25 | — | — | EP | claimed |
| US-6133261-A | THERAPEUTIC METHOD FOR TREATING OR PREVENTING STROKE AND OTHER ISCHEMIC DISORDERS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2000-10-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128377-A1 | METHODS OF TREATING REFRACTORY REPETITIVE SEIZURES | GABRE, GRIK2, GABRR1 | SCN9A 255/4885CA12 624/4885CA1 60/4885 |
| US-20030171300-A1 | Treating different types and symptoms of acute and chronic pain, especially non neuropathic inflammatory pain in mammals. The pain to be treated may be e.g. chronic inflammatory pain, rheumatoid arthritis pain and/or secondary | OPRK1, OPRL1, PTGER1 | SCN9A 311/4885CA12 3621/4885CA1 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.